Clinical research
In Phase III EXPLORER-HCM clinical trial, mavacamten demonstrated a robust treatment effect and met all primary and secondary endpoints.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
Stéphane Bancel, Moderna’s chief executive officer, said the Phase II study is a crucial step in advancing the vaccine candidate as the company looks toward the goal of moving into Phase III.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
The therapy is being developed to decrease C. difficile (C. diff) infection recurrences.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
Sanofi and Regeneron are focusing on basal cell carcinoma treatment and their drug Libtayo is showing good results. The companies expect to make regulatory submissions this year.
Akebia Therapeutics’ investigational drug vadadustat hit the mark in the first of two Phase III trials in chronic kidney disease (CKD) patients who are on dialysis, and investors are pleased.
PRESS RELEASES